1) Murray PR, Baron EJ, Pfaller MA, et al (ed)u:uManual of Clinical Microbiology 7th ed. ASM,pp33-35,1999
2) Kersters K, Ludwig W, Vancanneyt M, et alu:uRecent change in the classification of the Pseudomonadsu:uan overview. Syst Appl Microbiol 19:465-477,1996
3) Palleroni NJ, Kunisawa R, Contopoulou R, et alu:uNucleic acid homologies in the genus Pseudomonas. Int J Syst Bact 23:333-339,1973
4) 荒川宜親:5)緑膿菌とその他のシュードモナス(Pseudomonas)属.畑中正一,嶋田甚五郎(編):微生物学.文光堂,pp203-208,1999
5) 宍戸春美,永井英明,西野武志:22. 非発酵グラム陰性桿菌.松本慶蔵(編):新・病原菌の今日的意味.医薬ジャーナル社,pp332-347,1992
6) 前田光一,三笠桂一:3耐性菌の基礎と臨床 主として院内感染で問題となる耐性菌・2緑膿菌(臨床編).臨床検査 50:468-471,2006
7) Clinical and Laboratory Standards Instituteu:uPerformance standards for antimicrobial susceptibility testingu;u17th the informational supplement, M7-A7. CLSI, Wayne,2004
8) Craig WAu:uPharmacokinetic/pharmacodynamic parametersu:urationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12,1998
9) Craig WAu:uDoes the dose matter? Clin Infect Dis 33(suppl):S233-S237,2001
10) Kuti JL, Dandeker PK, Nightingale CH, et alu:uUse of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Phamacol 43:1116-1123,2003
11) Walker R, Andes D, Conklin J, et alu:u34th ICAAC Abstr A-91,1994